AI to predict mHSPC outcomes and stra... - Fight Prostate Ca...

Fight Prostate Cancer

2,949 members1,290 posts

AI to predict mHSPC outcomes and strategies

Maxone73 profile image
2 Replies

Of course, how the tool works and if it's already protected by a patent is unknown...but...

A new study shows how artificial intelligence (AI) can help predict outcomes for men with advanced prostate cancer. Researchers used an AI tool to analyze tissue samples and clinical data, creating a score that identifies patients at high, medium, or low risk of poor outcomes.

Patients with low-risk scores had an 83% chance of surviving 5 years, compared to just 39% for high-risk patients.

This tool could help doctors personalize treatments, choosing the best options for each patient while avoiding over- or under-treatment. The findings bring hope for more effective and tailored care in advanced prostate cancer.

prostatewarriors.com/2025/0...

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...
2 Replies
janebob99 profile image
janebob99

Hi, Maxone73.

I wish to disagree with your first sentence.

You seem to imply that having a patent makes the invention a secret.

The reality is just the opposite. Patenting an invention requires the patent owner to disclose all of the enabling details of the invention to the public (i.e., in the patent document itself). This public disclosure allows other inventors to subsequently add improvements and then apply to get their own patent on their improved version.

(I have been a registered Patent Agent in the USA for over 25 years.)

Bob in New Mexico

Maxone73 profile image
Maxone73 in reply tojanebob99

There is not disagreement...it's a secret while it is not protected by a patent or while in the process, and that part we don't know. But yes, my words could be misinterpreted!

Not what you're looking for?

You may also like...

BLUE SKY NEWS - AUGUST 2022

While some of the content of the August edition of the Blue Sky New’s publication from...
marnieg46 profile image

SBRT Added to Standard Tx Boosts Outcomes in Oligometastatic PCa - ARTO II~ Improved response & PFS compared to SOC, MedPage Today, 09/27/23

SBRT Added to Standard Tx Boosts Outcomes in Oligometastatic Prostate Cancer — Combination...
cujoe profile image

EMBARK Study: Enzalutamide +/- ADT

Results of the EMBARK study was published this week (10/19/23) in NEJM. It compared high risk BCR...

Alicia Morgans, MD, on PCa in Older Men – Determining frailty or fitness will help guide treatment decisions, MedPageToday, 11/27/2023

Those who dig deep into research methodologies know well the inherent biases that riddle much...
cujoe profile image

Risk Management (Taleb-style) meets Adaptive Theory (Moffitt-style)

Those who know of the generational genius thinker, Nassim Taleb, should already be familiar with...
cujoe profile image